KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Intangibles (2020 - 2025)

AbCellera Biologics' Intangibles history spans 6 years, with the latest figure at $39.3 million for Q3 2025.

  • For the quarter ending Q3 2025, Intangibles fell 25.21% year-over-year to $39.3 million, compared with a TTM value of $39.3 million through Sep 2025, down 25.21%, and an annual FY2024 reading of $42.1 million, down 65.03% over the prior year.
  • Intangibles for Q3 2025 was $39.3 million at AbCellera Biologics, down from $40.3 million in the prior quarter.
  • The five-year high for Intangibles was $161.0 million in Q2 2022, with the low at $11.3 million in Q4 2021.
  • Average Intangibles over 5 years is $100.3 million, with a median of $118.7 million recorded in 2024.
  • Biggest YoY gain for Intangibles was 834460.28% in 2021; the steepest drop was 90.19% in 2021.
  • Tracing ABCL's Intangibles over 5 years: stood at $11.3 million in 2021, then surged by 1063.73% to $131.5 million in 2022, then dropped by 8.42% to $120.4 million in 2023, then tumbled by 65.03% to $42.1 million in 2024, then fell by 6.63% to $39.3 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Intangibles are $39.3 million (Q3 2025), $40.3 million (Q2 2025), and $41.2 million (Q1 2025).